Class / Patent application number | Description | Number of patent applications / Date published |
514170400 | Ion channel protein affecting | 20 |
20110144028 | MODULATING CELLULAR ELECTROPHYSIOLOGY - The present invention relates to compositions, apparatus, and methods for improving the viability of cells, including, but not limited to, nonexcitable cells, and tissues expressing exogenous polynucleotides that encode membrane proteins that regulate that flow of ions across the cell membrane. The viability of the cells and tissues may be improved by contacting the cells or tissue with one or more ion channel blocking agents. Membrane proteins that regulate the flow of ions across the cell membrane include, but are not limited to, ion channels. | 06-16-2011 |
20110152197 | ANALGESIC EFFECTS OF PEPTIDE TOXIN APETX2 - The invention relates to the use of the peptide toxin APETx2 that blocks the ASIC3 cationic channels and that is derived from the | 06-23-2011 |
20120040909 | IDENTIFICATION OF NOVEL ANTAGONIST TOXINS OF T-TYPE CALCIUM CHANNEL FOR ANALGESIC PURPOSES - A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic one. | 02-16-2012 |
20120115789 | Methylglyoxal-Scavenging Compounds and Their Use for the Prevention and Treatment of Pain and/or Hyperalgesia - The present invention relates to compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein, preferably an arginine- or lysine-containing cellular protein, such as a sodium ion channel, e.g. the sodium ion channel Na(v)1.8. Preferred scavenger compounds are peptides comprising several or multiple repeats of the amino acid sequence motif Gly-Glu-X-Pro (GEXP), wherein X is Arg or Lys, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the compounds as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the compounds for the prevention and/or treatment of pain, hyperalgesia and pain related diseases, in particular pain and/or hyperalgesia caused by or associated with methylglyoxal and/or reactive carbonyl species (RCS). | 05-10-2012 |
20120142600 | Analogs of ShK Toxin and their Uses in Selective Inhibition of Kv1.3 Potassium Channels - Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore and such fluorophore-tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells. | 06-07-2012 |
20120165265 | Calcium Signaling Modulators Involving STIM and ORAI Proteins - The present invention provides compositions and methods for investigating the structural basis of the activation process of CRAC channels, which are essential for T-lymphocyte activation and adaptive immunity. The invention also provides compositions and methods to design, identify and evaluate agents that modulate calcium signaling by regulating the interaction between STIM and Orai proteins. The invention also provides therapeutic agents for cases of immunological disorders, compromised immune function, organ transplantation, or thrombosis. | 06-28-2012 |
20120316119 | PEPTIDE COMPOSITION FOR CANCER TREATMENT BY INHIBITING TRPV6 CALCIUM CHANNEL ACTIVITY - The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer. | 12-13-2012 |
20130184218 | Targeted Osmotic Lysis of Cancer Cells - A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na | 07-18-2013 |
20130244944 | Synthetic Ion Channels - Provided herein are self-assembling compounds that can form ion channels in lipid bilayers or cell membranes and ion-channel-forming compositions comprising the self-assembling compounds. Also provided are methods of making and using the ion channels formed from a plurality of molecules of the self-assembling compounds. Further, provided are methods of treating or preventing conditions and diseases that are related to the dysfunction of ion channels, including chloride channels. | 09-19-2013 |
20130281379 | MUTANT CHANNELRHODOPSIN 2 - The invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses. | 10-24-2013 |
20130288974 | METHOD FOR AMELIORATING PAIN BY MODIFICATION OF NMDA RECEPTORS THROUGH INHIBITION OF SRC - The present invention provides a method for ameliorating inflammatory and/or neuropathic pain in a subject by modifying the activity of N-methyl-D-aspartate (NMDA) receptors in cells of the subject by inhibition of the interaction of the unique domain of the tyrosine kinase Src enzyme and the NMDA receptor complex. | 10-31-2013 |
20130296247 | Analogs of Sodium Channel Peptide Toxin - The present invention relates to a peptide and analogs thereof that selectively inhibit the Na | 11-07-2013 |
20140187493 | PEPTIDE COMPOSITION FOR CANCER TREATMENT BY INHIBITING TRPV6 CALCIUM CHANNEL ACTIVITY - The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer. | 07-03-2014 |
20140256644 | Treatment of Muscular Conditions and Muscular Dystrophies - The present invention provides methods for improving muscular function or treating a muscular disorder in an individual by administering to the individual a pharmacologically effective amount of a compound that inhibits microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production. In addition compounds that block sarcolemmal Ca | 09-11-2014 |
20150045305 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS - Described herein is a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising administration of an effective amount of one or more of a potassium channel blocker and an effective amount of one or more of a late sodium channel blocker. Also provided are methods for modulating ventricular and atrial rhythm and rate. Also provided are pharmaceutical formulations that are suitable for such combined administration. | 02-12-2015 |
20150099705 | PROTOXIN -II VARIANTS AND METHODS OF USE - The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing. | 04-09-2015 |
20150369819 | TMEM120A ION CHANNEL MODULATOR - Assays for selecting a candidate modulator of a TMEM120A ion channel and/or a candidate modulator of chronic pain, the steps comprising contacting a lipid membrane comprising contacting a lipid membrane comprising TMEM120A polypeptide with a test compound; quantitating the TMEM120A ion channel activity; comparing the ion channel activity of the TMEM120A polypeptide with a control; and selecting the test compound that modulates the ion channel activity compared to the control; and methods and compositions for treating chronic pain including osteoarthritic pain. | 12-24-2015 |
20160015782 | Analogs of ShK Toxin and Their Uses in Selective Inhibition of Kv1.3 Potassium Channels - Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog. Such fluorophore tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells. | 01-21-2016 |
20160102121 | Peptide Inhibitors of Sodium Channels - The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels. | 04-14-2016 |
20160152671 | CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USES THEREOF | 06-02-2016 |